共 57 条
[1]
Tournigand C(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 15 229-237
[2]
André T(2016)Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) Ann Oncol 27 1539-1546
[3]
Achille E(2017)Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab Cancer Chemother Pharmacol 79 579-585
[4]
Yamazaki K(2012)Intra-arterial infusion of irinotecan-loaded drug eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study Anticancer Res 32 1387-1395
[5]
Nagase M(2015)Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases World Journal of Surgery 40 1178-1190
[6]
Tamagawa H(2011)Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Ann Surg Oncol 18 192-198
[7]
Kuramochi H(2015)Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis Cardiovasc Intervent Radiol 38 361-371
[8]
Ando M(2013)FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study Cancer Chemother Pharmacol 72 1097-1102
[9]
Itabashi M(2013)Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model J Mater Sci Mater Med 24 115-127
[10]
Fiorentini G(2010)Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry Cardiovasc Intervent Radiol 33 960-966